SOAT1 and myeloproliferative disorder: Despite the lack of molecular response observed in the majority of ruxolitinib-treated MPN patients (Harrison et al. 2012; Verstovsek et al. 2012), genetic studies have demonstrated that MPN cells are indeed reliant on aberrant JAK/STAT signaling, underscoring its relevance as a therapeutic target in this disease (Bhagwat et al. 2014).